Pharmaceutical

Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in 2026.

Apr 18, 2025 - 06:00
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in 2026.
Read the original article

Tags:

Previous Article

UTA’s 23 Patents Bolster UT System’s Position as No. 3 in National Academy of In...

Next Article

FDA to review Regeneron’s sBLA for aflibercept injection 8mg

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Imunon’s shares soar after IL-12 therapy success in Phase II trial

Imunon’s shares soar after IL-12 therapy success in Pha...

Aug 1, 2024

Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy

Novaliq and Laboratoires Théa announce EC approval for ...

Oct 4, 2024

DMD market expected to grow to $5.2bn in the 7MM by 2033

DMD market expected to grow to $5.2bn in the 7MM by 2033

Feb 15, 2025